Business Wire

MD-TELEDYNE-FLIR

8.3.2022 13:03:05 CET | Business Wire | Press release

Share
As Drone Strikes Rise, Multi-Layered Approach is Crucial to Countering New and Emerging Threats

In a new whitepaper, Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), finds that a multi-layered approach, incorporating common architectures and information sharing, among other imperatives, is needed to address the threat to life and property posed by weaponized use of small Unmanned Aerial Systems (sUAS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308005265/en/

In January, non-state actors from Yemen utilized small unmanned aerial systems to launch deadly attacks in the United Arab Emirates that destroyed three refueling vehicles and damaged Abu Dhabi’s international airport. Other drone incidents in the Persian Gulf region include a 2019 strike on the world’s largest oil processing facility in Saudi Arabia.

The whitepaper, ‘The Big Problem with Small Drones (and How to Address It) ,’ examines how governments worldwide face a growing need for flexible, tailorable, and affordable Counter-sUAS (C-sUAS) solutions. It looks at current C-sUAS strategy, identifies key challenges, and outlines the critical capabilities governments should consider.

“There’s no ‘silver bullet’ when it comes to countering the huge risks presented by weaponized drones in the hands of bad actors,” said Dr. David Cullin, vice president and general manager of Unmanned and Integrated Solutions at Teledyne FLIR Defense. “What we’ve learned is that governments must address a host of challenges in concert to optimize their defense readiness in the face of UAS attacks.

“Nations around the globe are spending millions of dollars on commercially-built counter-drone solutions to address the immediate risks posed by these threats. But they need to approach the problem smartly, both from a technology and cost perspective. Our new whitepaper offers a number of insights from our team of experts,” Cullin adds.

Key findings include:

  • State and non-state actors are increasingly employing military- and consumer-grade drones to attack personnel, facilities and critical infrastructure
  • Counter-drone solutions must be cost effective, leveraging existing technologies through common electronic architectures and standard interfaces to ensure rapid integration of hardware and software upgrades
  • Solutions must be modular, interoperable and multi-domain; easily transportable; and capable of detecting drone swarms
  • Modern C-sUAS must be able to operate in contested environments where the ability to find, track, target, engage and assess threats can be disrupted by peer adversaries’ electronic warfare capabilities
  • Current and future C-sUAS systems must be flexible in employing both hard kill (kinetic) and soft kill (non-kinetic) countermeasures, allowing them to operate anywhere in the world in accordance with local restrictions and rules of engagement.

As the paper sums up, ‘The threat of small drones in the wrong hands promises to remain significant for government and military decision-makers as they seek to defend forward-deployed units, airports, power grids, and other critical infrastructure. Only the deployment of mature, flexible, and cost effective C-sUAS solutions will provide the required levels in protection as this threat continues to evolve at pace.”

About Teledyne FLIR

Teledyne FLIR, a Teledyne Technologies company, is a world leader in intelligent sensing, unmanned systems, and integrated solutions for defense and industrial markets, with roughly 4,000 employees worldwide. Founded in 1978, the company develops a wide range of advanced technologies to help professionals make better, faster decisions that save lives and livelihoods. To learn more, visit teledyneflir.com or follow @flir. #AnyThreatAnywhere

About Teledyne Technologies

Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye